The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
GSK-3 inhibitor elraglusib (9-ING-41) to enhance tumor-infiltrating immune cell activation in tumor biopsies and synergize with anti-PD-L1 in a murine model of colorectal cancer.
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Chimerix; Oncoceutics; p53-Therapeutics; SMURF-Therapeutics
Consulting or Advisory Role - Rain Therapeutics
Research Funding - Chimerix; D&D Pharmatech
Patents, Royalties, Other Intellectual Property - Patent on therapeutic targeting on hypoxia-inducible factors; Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
(OPTIONAL) Uncompensated Relationships - As above
 
Kelsey Huntington
No Relationships to Disclose
 
Anna Louie
Research Funding - Oncoceutics (Inst)
 
Praveen Srinivasan
No Relationships to Disclose
 
Cristoph Schorl
No Relationships to Disclose
 
Shaolei Lu
No Relationships to Disclose
 
David Silverberg
No Relationships to Disclose
 
Daniel Newhouse
No Relationships to Disclose
 
Zhijin Wu
No Relationships to Disclose
 
Lanlan Zhou
No Relationships to Disclose
 
Dinara Ryspayeva
No Relationships to Disclose
 
Brittany Borden
No Relationships to Disclose
 
Francis J. Giles
No Relationships to Disclose
 
Mark Dooner
No Relationships to Disclose
 
Benedito A. Carneiro
Consulting or Advisory Role - Eisai; Seagen; Tempus
Research Funding - Abbvie (Inst); Actuate Therapeutics (Inst); Agenus (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Dragonfly Therapeutics (Inst); MiNK Therapeutics (Inst); Pfizer (Inst); Repare Therapeutics (Inst)